Forskellen skyldtes udfaldet i gruppen af orlistatbehandlede patienter med ≥ 5% vægttab efter 12 ugers behandling, hvilket svarede til 19% af den initiale population.
The difference was driven by the outcome in the group of patients with ≥ 5% weight loss after 12 weeks of treatment with orlistat representing 19% of the initial population.